Put companies on watchlist
Galenica AG
ISIN: CH0360674466
WKN: A2DN0K
Curious about what AI knows about Galenica? Just one click more
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Galenica AG · ISIN: CH0360674466 · EQS - Company News (16 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 2111546
10 April 2025 06:12PM

Galenica Annual General Meeting approves all motions and elects new member of the Board of Directors


Galenica AG / Key word(s): AGMEGM
Galenica Annual General Meeting approves all motions and elects new member of the Board of Directors

10.04.2025 / 18:12 CET/CEST


Press release

  • All motions of the Board of Directors approved with broad consensus
  • Nadine Balkanyi-Nordmann elected as a new member of the Board of Directors
  • Dividend of CHF 2.30 per share approved – increase of 4.5%

The eighth Annual General Meeting of Galenica Ltd. was attended by 367 shareholders, representing a total of 70.5% of the registered voting shares of Galenica Ltd. They approved all the motions put forward by the Board of Directors, including the 2024 financial statements of Galenica Ltd., the management report, the report on non-financial matters and the consolidated financial statements of the Galenica Group.

 

Markus Neuhaus, Chairman of the Board of Directors of Galenica: “The favourable ballot results confirm that our Group is heading in the right direction in terms of strategy, personnel and operations. The annual result underscores our outstanding position as the largest healthcare network in Switzerland.”

 

Dividend increase of 4.5% to CHF 2.30 per share

The shareholders also approved an increase in the dividend for the past financial year to CHF 2.30 per share (previous year: CHF 2.20). This is the fifth increase in the dividend in the past eight years. A total expected distribution of CHF 114.6 million will be paid out. Galenica aims for strong and sustainable dividend growth, and plans to keep the dividend for 2025 at the previous year’s level at least.

 

Election of Nadine Balkanyi-Nordmann to the Board of Directors

Nadine Balkanyi-Nordmann was elected as a new member of the Board of Directors with 99.4% of the votes. Following the death of Dr. Andreas Walde, the Board of Directors now consists of seven members again. The existing members of the Board of Directors and the Chairman of the Board of Directors Dr. Markus R. Neuhaus were also re-elected for another term of office of one year with very broad consensus.

 

General Meeting adopts all motions

The General Meeting also approved the actions of the Board of Directors and the Executive Committee for the 2024 financial year and agreed to the 2024 remuneration report in a consultative vote. 96.9% of those eligible to vote also approved the remuneration framework for 2026 for both the Board of Directors as well as the Executive Committee.

 

All voting results and the minutes of the General Meeting will be published on the Galenica website at the earliest opportunity.

Dates for the diary

22 May 2025: Galenica Group sales update
7 August 2025: Publication of Galenica Group half-year results 2025
23 October 2025: Galenica Group sales update
28 October 2025: Galenica Investor Day 2025

 

For further information, please contact:

 

Media Relations:
Iris Müller, Chief Communications Officer
Tel. +41 58 852 85 17
E-Mail:
media@galenica.com
Investor Relations:
Julian Fiessinger, CFO
Tel. +41 58 852 85 31
E-Mail:
investors@galenica.com

Welcome to the Galenica network!
Around 8,000 employees at Galenica work tirelessly to improve the health and well-being of the people of Switzerland every day. With its pharmacies, pharmaceutical logistics providers, products, services and home care, Galenica has a broad and successful position in the market. We are shaping the future of healthcare in collaboration with our strong partners – by drawing on the diverse skills and extensive expertise of our entire network. Our ambition is to fulfil the needs of customers and patients in the Swiss healthcare market seamlessly, efficiently and personally.

Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Additional information about Galenica can be found at www.galenica.com.



End of Media Release


Language: English
Company: Galenica AG
Untermattweg 8
3027 Bern
Switzerland
Phone: +41 058 852 81 11
E-mail: info@galenica.com
Internet: https://www.galenica.com
ISIN: CH0360674466
Listed: SIX Swiss Exchange
EQS News ID: 2111546

 
End of News EQS News Service

2111546  10.04.2025 CET/CEST

Visual performance / price development - Galenica AG
Smart analysis and research tools can be found here.
MIC: XSWX

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.